RVLP Stock Overview
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.
RVL Pharmaceuticals plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.47|
|52 Week High||US$2.99|
|52 Week Low||US$0.98|
|1 Month Change||-18.33%|
|3 Month Change||-31.31%|
|1 Year Change||3.52%|
|3 Year Change||-78.01%|
|5 Year Change||n/a|
|Change since IPO||-81.96%|
Recent News & Updates
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of DebtJul 04
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)Apr 01
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of DebtAug 20
These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt ExtensivelyMay 05
An Intrinsic Calculation For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Suggests It's 33% UndervaluedMar 24
Osmotica Pharmaceuticals'(NASDAQ:OSMT) Share Price Is Down 35% Over The Past Year.Mar 01
Are Institutions Heavily Invested In Osmotica Pharmaceuticals plc's (NASDAQ:OSMT) Shares?Feb 01
Osmotica Pharmaceuticals plc (NASDAQ:OSMT): Is Breakeven Near?Jan 04
Here's Why Osmotica Pharmaceuticals (NASDAQ:OSMT) Can Manage Its Debt ResponsiblyDec 09
|RVLP||US Pharmaceuticals||US Market|
Return vs Industry: RVLP underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: RVLP exceeded the US Market which returned -18.5% over the past year.
|RVLP Average Weekly Movement||11.0%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: RVLP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: RVLP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc Fundamentals Summary
|RVLP fundamental statistics|
Is RVLP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RVLP income statement (TTM)|
|Cost of Revenue||US$7.98m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.54|
|Net Profit Margin||-124.02%|
How did RVLP perform over the long term?See historical performance and comparison